Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity

Authors: Birgit Lohberger, Nicole Stuendl, Elisabeth Wolf, Bernadette Liegl-Atzwanger, Andreas Leithner, Beate Rinner

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Myxofibrosarcoma comprises a spectrum of malignant neoplasms withprominent myxoid stromata, cellular pleomorphism, and distinct curvilinear vascular patterns. These neoplasms mainly affect patients in the sixth to eighth decades of life and the overall 5-year survival rate is 60–70%.

Methods

After the establishment of the novel myxofibrosarcoma cell lines MUG-Myx1, cells were characterized using short tandem repeat (STR), copy number variation (CNV), and genotype/loss-of-heterozygosity (LOH) analyses. The growth behaviour of the cells was analyzed with the xCELLigence system and an MTS assay. The tumourigenicity of MUG-Myx1 was proved in NOD/SCID mice. Additionally, a stem-like cell population with high enzymatic activity of aldehyde dehydrogenase 1 (ALDH1high) was isolated for the first time from myxofibrosarcoma cells using the Aldefluor® assay followed by FACS analysis.

Results

The frozen primary parental tumour tissue and the MUG-Myx1 cell line showed the same STR profile at the markers D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D, Amelogenin, D8S1179, TPOX, and FGY. Typically, myxofibrosarcoma gain and/or amplification was mapped to 7p21.3-q31.1, q31.1-q31.33, q33-q36.2, p21.3, p21.2, p14.1-q11.23, q31.33-q33, p21.2-p14.1, q11.23-q21.3, q36.2-q36.3, which, respectively are known to harbour tumour-associated genes, including TIF, BRAF, MLL3, SMO, and MET. Typically an LOH for myxofibrosarcoma on chr5 q21 was found. In addition, MUG-Myx1 ALDH1high cells showed an upregulation of the ABC transporter ABCB1 and ABCG2; higher c-Myc, E-cadherin and SOX-2 expression; and a higher potential for tumourigenicity and proliferation levels.

Conclusion

The new myxofibrosarcoma cell line MUG-Myx1 was established to enrich the bank of publicly available cell lines, with respect to providing comprehensive genetic and epigenetic characterization. Furthermore, because of their tumourigenicity, the cell line is also suitable for in vivo experiments.
Appendix
Available only for authorised users
Literature
1.
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F: Myxofibrosarcoma. WHO Classification of Tumors of Soft Tissue and Bone. 2013, Geneva (Switzerland): World Health Organization Classification of Tumors, 93-94. 4
2.
Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR: Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004, 35: 612-621. 10.1016/j.humpath.2004.01.016.CrossRefPubMed
3.
Lin CN, Chou SC, Li CF, Tsai KB, Chen WC, Hsiung CY, Yen CF, Huang HY: Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2004, 93: 294-303.CrossRef
4.
Huang HY, Huang WW, Wu JM, Huang CK, Wang JW, Eng HL, Lin CN, Chou SC, Yu SC, Fang FM, Lee JC, Li CF: Flow cytometric analysis of DNA ploidy and S-phase fraction in primary localized myxofibrosarcoma: correlations with clinicopathological factors, Skp2 expression, and patient survival. Ann Surg Oncol. 2008, 15: 2239-2249. 10.1245/s10434-008-9968-0.CrossRefPubMed
5.
Hajj MA, Clarke MF: Self-renewal and solid tumor stem cells. Oncogene. 2004, 23: 74-82.
6.
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006, 66: 9339-9344. 10.1158/0008-5472.CAN-06-3126.CrossRefPubMed
7.
Ginestier C, Hur MH, Charafe-Jauffret E, Monvile F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 15: 555-567.CrossRef
8.
Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A: Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67: 2187-2196. 10.1158/0008-5472.CAN-06-3281.CrossRefPubMedPubMedCentral
9.
Balicki D: Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007, 15: 485-487.CrossRef
10.
Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A: Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One. 2012, 7 (8): e43664-10.1371/journal.pone.0043664.CrossRefPubMedPubMedCentral
11.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009, 55 (4): 611-622. 10.1373/clinchem.2008.112797.CrossRefPubMed
12.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3 (7): RESEARCH0034-CrossRefPubMedPubMedCentral
13.
Weiss SW, Enzinger FM: Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977, 39: 1672-1685. 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C.CrossRefPubMed
14.
Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD: Myxofibrosarcoma. Clinicopathological analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996, 20: 391-405.CrossRefPubMed
15.
Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A: Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011, 18: 720-725. 10.1245/s10434-010-1341-4.CrossRefPubMed
16.
Jefford CE, Irminger-Finger I: Mechanisms of chromosome instability in cancers. Crit Rev Oncol Hematol. 2006, 59: 1-14. 10.1016/j.critrevonc.2006.02.005.CrossRefPubMed
17.
Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005, 5: 773-785. 10.1038/nrc1714.CrossRefPubMed
18.
Slominski A, Wortsman J, Carlson A, Mihm M, Nickoloff B, McClatchey K: Molecular pathology of soft tissue and bone tumors. A review. Arch Pathol Lab Med. 1999, 23: 1246-1259.
19.
Conway C, Chalkley R, High A, Maclennan K, Berri S, Chengot P, Alsop M, Egan P, Morgan J, Taylor GR, Chester J, Sen M, Rabbitts P, Wood HM: Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn. 2012, 14 (2): 104-111. 10.1016/j.jmoldx.2011.10.003.CrossRefPubMed
20.
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG: Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001, 29: 263-264. 10.1038/ng754.CrossRefPubMed
21.
Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I: Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005, 85 (3): 408-415. 10.1038/labinvest.3700230.CrossRefPubMed
22.
Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P, Barr FG: Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002, 33: 310-321. 10.1002/gcc.10026.CrossRefPubMed
23.
Ohguri T, Hisaoka M, Kawauchi S, Sasaki K, Aoki T, Kanemitsu S, Matsuyama A, Korogi Y, Hashimoto H: Cytogenetic analysis of myxoid liposarcoma and myxofibrosarcoma by array-based comparative genomic hybridisation. J Clin Pathol. 2006, 59: 978-983. 10.1136/jcp.2005.034942.CrossRefPubMedPubMedCentral
24.
Stock C, Kager L, Fink FM, Gadner H, Ambros PF: Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer. 2000, 28: 329-336. 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F.CrossRefPubMed
25.
Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Böhling T, Ekfors T, Virolainen M, Lindholm P, Monge O, Picci P, Knuutila S, Elomaa I: Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet. 1999, 114: 35-41. 10.1016/S0165-4608(99)00031-X.CrossRefPubMed
26.
Tarkkanen M, Wiklund TA, Virolainen MJ, Larramendy ML, Mandahl N, Mertens F, Blomqvist CP, Tukiainen EJ, Miettinen MM, Elomaa AI, Knuutila YS: Comparative genomic hybridization of postirradiation sarcomas. Cancer. 2001, 92: 1992-1998. 10.1002/1097-0142(20011001)92:7<1992::AID-CNCR1719>3.0.CO;2-2.CrossRefPubMed
27.
Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY: Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 2010, 23 (10): 1379-1392. 10.1038/modpathol.2010.128.CrossRefPubMed
28.
Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, Yu SC, Lan J, Huang HY: Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol. 2012, 19 (8): 2716-2725. 10.1245/s10434-012-2317-3.CrossRefPubMed
29.
Tuna M, Ju Z, Amos CI, Mills GB: Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy. BMC Med Genomics. 2012, 5: 60-67. 10.1186/1755-8794-5-60.CrossRefPubMedPubMedCentral
30.
Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R: Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006, 19 (3): 407-416. 10.1038/modpathol.3800550.CrossRefPubMed
31.
Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, Chen YL, DeLaney TF, Nielsen GP, Mullen JT: Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013, 20 (1): 80-86. 10.1245/s10434-012-2572-3.CrossRefPubMed
32.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed
33.
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67: 1030-1037. 10.1158/0008-5472.CAN-06-2030.CrossRefPubMed
34.
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Strass SA, Katz RL: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009, 7: 330-338. 10.1158/1541-7786.MCR-08-0393.CrossRefPubMedPubMedCentral
35.
Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME: Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010, 32: 1195-1201. 10.1002/hed.21315.CrossRefPubMedPubMedCentral
36.
Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G: Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010, 70: 8874-8885. 10.1158/0008-5472.CAN-10-1994.CrossRefPubMed
37.
An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol. 2009, 5 (12): 1529-1542. 10.1517/17425250903228834.CrossRefPubMed
38.
Ding XW, Wu JH, Jiang CP: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010, 86: 631-637. 10.1016/j.lfs.2010.02.012.CrossRefPubMed
39.
Murphy MJ, Wilson A, Trumpp A: More than just proliferation: Myc function in stem cells. Trends Cell Biol. 2005, 15: 128-137. 10.1016/j.tcb.2005.01.008.CrossRefPubMed
40.
Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126: 663-676. 10.1016/j.cell.2006.07.024.CrossRefPubMed
41.
Croker AK, Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012, 133 (1): 75-81. 10.1007/s10549-011-1692-y.CrossRefPubMed
42.
Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A: Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One. 2011, 6 (7): e22118-10.1371/journal.pone.0022118.CrossRefPubMedPubMedCentral
Metadata
Title
The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity
Authors
Birgit Lohberger
Nicole Stuendl
Elisabeth Wolf
Bernadette Liegl-Atzwanger
Andreas Leithner
Beate Rinner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-563

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer

Case report

Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation

Research article

Design and application of a novel PNA probe for the detection at single cell level of JAK2V617Fmutation in Myeloproliferative Neoplasms

Research article

BRCA1 and ERCC1mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer

Research article

Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)

Study protocol

The life in sight application study (LISA): design of a randomized controlled trial to assess the role of an assisted structured reflection on life events and ultimate life goals to improve quality of life of cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits